Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GeoPharma, a manufacturer and distributor of private-label dietary supplements, generic drugs, and health and beauty products, has signed an agreement with Trident Biotech, for the sale of a majority stake in the company's ovarian cancer business.
Subscribe to our email newsletter
GeoPharma receives $2.5 million in cash and notes and will maintain 40% ownership in the business under the terms of the agreement.
GeoPharma hopes that the formation of this partnership will help proliferate the commercialization of early detection and monitoring devices for ovarian cancer and improve the quality of healthcare for women everywhere.
Mihir Taneja, CEO of GeoPharma, said: “This transaction strengthens our financial and competitive position in our core business and eases the burden of funding our ovarian cancer business segment while allowing us to remain a significant partner in a technology we are extremely passionate about.”